Selected research
Industry Research
Circular mRNA Drugs Industry Research Report 2026
Market perspective
The global Circular mRNA Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Circular mRNA Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Circular mRNA Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Circular mRNA Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Circular mRNA Drugs include Chimera Therapeutics, Orbital Therapeutics, Orna Therapeutics, Sail Biomedicines, Torque Bio, Aikang Pharmaceuticals, Edigene, CirCode and Curemed Bio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Circular mRNA Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Circular mRNA Drugs Market by Company
Chimera Therapeutics
Orbital Therapeutics
Orna Therapeutics
Sail Biomedicines
Torque Bio
Aikang Pharmaceuticals
Edigene
CirCode
Curemed Bio
Therorna
Circular mRNA Drugs Segment by Type
Preventive Medicine
Medicine
Circular mRNA Drugs Segment by Application
Infectious Disease
Cancer
Others
Circular mRNA Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circular mRNA Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Circular mRNA Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circular mRNA Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Circular mRNA Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Circular mRNA Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Circular mRNA Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Preventive Medicine
- Medicine
Applications
- Infectious Disease
- Cancer
- Others
Companies covered
- Chimera Therapeutics
- Orbital Therapeutics
- Orna Therapeutics
- Sail Biomedicines
- Torque Bio
- Aikang Pharmaceuticals
- Edigene
- CirCode
- Curemed Bio
- Therorna
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Circular mRNA Drugs Market Size (2021-2032)
- 2.2.2 Global Circular mRNA Drugs Sales (2021-2032)
- 2.2.3 Global Circular mRNA Drugs Market Average Price (2021-2032)
- 2.3 Circular mRNA Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Preventive Medicine
- 2.3.3 Medicine
- 2.4 Circular mRNA Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Infectious Disease
- 2.4.3 Cancer
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Circular mRNA Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Circular mRNA Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Circular mRNA Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Circular mRNA Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Circular mRNA Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Circular mRNA Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Circular mRNA Drugs, Product Type & Application
- 3.8 Global Manufacturers of Circular mRNA Drugs, Established Date
- 3.9 Global Circular mRNA Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Chimera Therapeutics
- 4.1.1 Chimera Therapeutics Company Information
- 4.1.2 Chimera Therapeutics Business Overview
- 4.1.3 Chimera Therapeutics Circular mRNA Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Chimera Therapeutics Circular mRNA Drugs Product Portfolio
- 4.1.5 Chimera Therapeutics Recent Developments
- 4.2 Orbital Therapeutics
- 4.2.1 Orbital Therapeutics Company Information
- 4.2.2 Orbital Therapeutics Business Overview
- 4.2.3 Orbital Therapeutics Circular mRNA Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Orbital Therapeutics Circular mRNA Drugs Product Portfolio
- 4.2.5 Orbital Therapeutics Recent Developments
- 4.3 Orna Therapeutics
- 4.3.1 Orna Therapeutics Company Information
- 4.3.2 Orna Therapeutics Business Overview
- 4.3.3 Orna Therapeutics Circular mRNA Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Orna Therapeutics Circular mRNA Drugs Product Portfolio
- 4.3.5 Orna Therapeutics Recent Developments
- 4.4 Sail Biomedicines
- 4.4.1 Sail Biomedicines Company Information
- 4.4.2 Sail Biomedicines Business Overview
- 4.4.3 Sail Biomedicines Circular mRNA Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sail Biomedicines Circular mRNA Drugs Product Portfolio
- 4.4.5 Sail Biomedicines Recent Developments
- 4.5 Torque Bio
- 4.5.1 Torque Bio Company Information
- 4.5.2 Torque Bio Business Overview
- 4.5.3 Torque Bio Circular mRNA Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Torque Bio Circular mRNA Drugs Product Portfolio
- 4.5.5 Torque Bio Recent Developments
- 4.6 Aikang Pharmaceuticals
- 4.6.1 Aikang Pharmaceuticals Company Information
- 4.6.2 Aikang Pharmaceuticals Business Overview
- 4.6.3 Aikang Pharmaceuticals Circular mRNA Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Aikang Pharmaceuticals Circular mRNA Drugs Product Portfolio
- 4.6.5 Aikang Pharmaceuticals Recent Developments
- 4.7 Edigene
- 4.7.1 Edigene Company Information
- 4.7.2 Edigene Business Overview
- 4.7.3 Edigene Circular mRNA Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Edigene Circular mRNA Drugs Product Portfolio
- 4.7.5 Edigene Recent Developments
- 4.8 CirCode
- 4.8.1 CirCode Company Information
- 4.8.2 CirCode Business Overview
- 4.8.3 CirCode Circular mRNA Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 CirCode Circular mRNA Drugs Product Portfolio
- 4.8.5 CirCode Recent Developments
- 4.9 Curemed Bio
- 4.9.1 Curemed Bio Company Information
- 4.9.2 Curemed Bio Business Overview
- 4.9.3 Curemed Bio Circular mRNA Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Curemed Bio Circular mRNA Drugs Product Portfolio
- 4.9.5 Curemed Bio Recent Developments
- 4.10 Therorna
- 4.10.1 Therorna Company Information
- 4.10.2 Therorna Business Overview
- 4.10.3 Therorna Circular mRNA Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Therorna Circular mRNA Drugs Product Portfolio
- 4.10.5 Therorna Recent Developments
5 Global Circular mRNA Drugs Market Scenario by Region
- 5.1 Global Circular mRNA Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Circular mRNA Drugs Sales by Region: 2021-2032
- 5.2.1 Global Circular mRNA Drugs Sales by Region: 2021-2026
- 5.2.2 Global Circular mRNA Drugs Sales by Region: 2027-2032
- 5.3 Global Circular mRNA Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Circular mRNA Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Circular mRNA Drugs Revenue by Region: 2027-2032
- 5.4 North America Circular mRNA Drugs Market Facts & Figures by Country
- 5.4.1 North America Circular mRNA Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Circular mRNA Drugs Sales by Country (2021-2032)
- 5.4.3 North America Circular mRNA Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Circular mRNA Drugs Market Facts & Figures by Country
- 5.5.1 Europe Circular mRNA Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Circular mRNA Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Circular mRNA Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Circular mRNA Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Circular mRNA Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Circular mRNA Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Circular mRNA Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Circular mRNA Drugs Market Facts & Figures by Country
- 5.7.1 South America Circular mRNA Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Circular mRNA Drugs Sales by Country (2021-2032)
- 5.7.3 South America Circular mRNA Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Circular mRNA Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Circular mRNA Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Circular mRNA Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Circular mRNA Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Circular mRNA Drugs Sales by Type (2021-2032)
- 6.1.1 Global Circular mRNA Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Circular mRNA Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Circular mRNA Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Circular mRNA Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Circular mRNA Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Circular mRNA Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Circular mRNA Drugs Sales by Application (2021-2032)
- 7.1.1 Global Circular mRNA Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Circular mRNA Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Circular mRNA Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Circular mRNA Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Circular mRNA Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Circular mRNA Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Circular mRNA Drugs Value Chain Analysis
- 8.1.1 Circular mRNA Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Circular mRNA Drugs Production Mode & Process
- 8.2 Circular mRNA Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Circular mRNA Drugs Distributors
- 8.2.3 Circular mRNA Drugs Customers
9 Global Circular mRNA Drugs Analyzing Market Dynamics
- 9.1 Circular mRNA Drugs Industry Trends
- 9.2 Circular mRNA Drugs Industry Drivers
- 9.3 Circular mRNA Drugs Industry Opportunities and Challenges
- 9.4 Circular mRNA Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst